<unk>  may cause bone loss over time, and the loss in some women may not be completely recovered after stopping treatment. Because bone loss may increase the risk for fractures, women should not take<unk>  for more than 24 months. The drug label for the combination includes a boxed warning about the risk of vascular events (strokes) and thrombotic or thromboembolic disorders (blood clots), especially in women at increased risk for these events.
Elagolix/estradiol/norethindrone acetate
Estradiol enantate/algestone acetophenide
Relugolix/estradiol/norethisterone acetate
Ethinylestradiol/norethisterone
Estradiol undecylate/norethisterone enanthate
Segesterone acetate/ethinylestradiol
Ethinylestradiol/drospirenone
Ethinylestradiol/gestodene